Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the six-month period ended June 30, 2026. The report includes unaudited interim condensed consolidated financial statements, Management's Discussion and Analysis (MD&A), and a press release issued on August 12, 2026.
Key Financial Metrics
- Revenue Growth: The company reported 45% revenue growth year-over-year for the first half of 2026.
- Profit, Cash Flow, Margins, Debt, and Liquidity: The provided filing text does not provide clear values for net profit, operating cash flow, gross margins, total debt, or specific liquidity ratios. These details are contained within the attached exhibits (99.1 and 99.2) which are not included in the input text.
Material Changes
The primary material change highlighted in the filing is the significant year-over-year revenue increase of 45% for the six months ended June 30, 2026, compared to the same period in the prior year.
Guidance, Outlook, and Risks
The filing text references a press release titled "IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year" but does not contain specific forward-looking guidance, detailed management commentary, risk factors, or contingencies within the provided content. Investors must refer to the attached MD&A (Exhibit 99.2) and press release (Exhibit 99.3) for this information.
Investor Verification Checklist
- Verify the absolute revenue figures for the six months ended June 30, 2026, and the prior year period to confirm the 45% growth rate.
- Review the attached financial statements (Exhibit 99.1) for net loss, cash burn rate, and remaining cash on hand.
- Examine the MD&A (Exhibit 99.2) for details on the drivers of revenue growth and any changes in operating expenses.
- Check the press release (Exhibit 99.3) for any updated financial guidance or strategic milestones for the remainder of 2026.